{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:06:24Z","timestamp":1791925584974,"version":"4.3.4"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2015-02515"],"award-info":[{"award-number":["2015-02515"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Brain Foundation","doi-asserted-by":"publisher","award":["FO2018-0331"],"award-info":[{"award-number":["FO2018-0331"]}],"id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ibroneuroscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.neuroscience.2025.08.041","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T22:25:10Z","timestamp":1755987910000},"page":"404-411","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["The dopamine stabilizer (-)-OSU6162 attenuates levodopa-induced dyskinesia in the unilateral 6-hydroxydopamine rat model of Parkinson\u2019s disease"],"prefix":"10.1016","volume":"584","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9449-6791","authenticated-orcid":false,"given":"Daniela","family":"Atanasovski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Bergquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuroscience.2025.08.041_b0005","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.baga.2015.06.001","article-title":"The vulnerable ventral tegmental area in Parkinson's disease","volume":"5","author":"Alberico","year":"2015","journal-title":"Basal Ganglia"},{"key":"10.1016\/j.neuroscience.2025.08.041_b0010","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00213-013-3001-4","article-title":"The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat","volume":"227","author":"Bhide","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuroscience.2025.08.041_b0015","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s12640-019-00134-7","article-title":"OSU-6162, a sigma1r ligand in low doses, can further increase the effects of cocaine self-administration on accumbal D2R heteroreceptor complexes","volume":"37","author":"Borroto-Escuela","year":"2020","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.neuroscience.2025.08.041_b0020","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2023.1106765","article-title":"Combined treatment with Sigma1R and A2AR agonists fails to inhibit cocaine self-administration despite causing strong antagonistic accumbal A2AR-D2R complex interactions: the potential role of astrocytes","volume":"16","author":"Borroto-Escuela","year":"2023","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.neuroscience.2025.08.041_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.105044","article-title":"Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats","volume":"144","author":"Brugnoli","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuroscience.2025.08.041_b0030","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s00702-011-0701-y","article-title":"II. In vitro evidence that (-)-OSU6162 and (+)-OSU6162 produce their behavioral effects through 5-HT2A serotonin and D2 dopamine receptors","volume":"118","author":"Burstein","year":"2011","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.neuroscience.2025.08.041_b0035","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.nbd.2005.09.008","article-title":"Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia","volume":"21","author":"Carlsson","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuroscience.2025.08.041_b0040","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s00702-011-0704-8","article-title":"I. In vivo evidence for partial agonist effects of (-)-OSU6162 and (+)-OSU6162 on 5-HT2A serotonin receptors","volume":"118","author":"Carlsson","year":"2011","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.neuroscience.2025.08.041_b0045","doi-asserted-by":"crossref","first-page":"137","DOI":"10.31887\/DCNS.2006.8.1\/acarlsson","article-title":"A dopaminergic deficit hypothesis of schizophrenia: the path to discovery","volume":"8","author":"Carlsson","year":"2006","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.neuroscience.2025.08.041_b0050","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","article-title":"Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats","volume":"130","author":"Carta","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.neuroscience.2025.08.041_b0055","doi-asserted-by":"crossref","unstructured":"Cenci, M.A., Lundblad, M., 2007. Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice. Curr. Protoc. Neurosci. Chapter 9, Unit 9 25, doi:10.1002\/0471142301.ns0925s41 (2007).","DOI":"10.1002\/0471142301.ns0925s41"},{"key":"10.1016\/j.neuroscience.2025.08.041_b0060","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1471-4159.2006.04124.x","article-title":"Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia","volume":"99","author":"Cenci","year":"2006","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuroscience.2025.08.041_b0065","first-page":"2694","article-title":"L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA","volume":"10","author":"Cenci","year":"1998","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuroscience.2025.08.041_b0070","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1093\/brain\/awu195","article-title":"The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa","volume":"137","author":"Cilia","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.neuroscience.2025.08.041_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2023.114370","article-title":"Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease","volume":"363","author":"Corsi","year":"2023","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuroscience.2025.08.041_b0080","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1212\/01.WNL.0000110317.52453.6C","article-title":"Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study","volume":"62","author":"Durif","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.neuroscience.2025.08.041_b0085","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0028-3908(98)00200-7","article-title":"Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements of [11C]SCH23390 and [11C]raclopride binding in primate brains","volume":"38","author":"Ekesbo","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuroscience.2025.08.041_b0090","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1097\/00001756-199707280-00029","article-title":"(-)-OSU 6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinson's disease","volume":"8","author":"Ekesbo","year":"1997","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuroscience.2025.08.041_b0095","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0014-2999(99)00879-1","article-title":"Motor effects of (-)-OSU6162 in primates with unilateral 6-hydroxydopamine lesions","volume":"389","author":"Ekesbo","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuroscience.2025.08.041_b0100","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.3233\/JPD-212920","article-title":"Human embryonic stem cell-derived dopaminergic grafts alleviate L-DOPA induced dyskinesia","volume":"12","author":"Elabi","year":"2022","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.neuroscience.2025.08.041_b0105","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","article-title":"Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects","volume":"49","author":"Farde","year":"1992","journal-title":"Arch. Gen. Psychiatry"},{"issue":"Suppl 3","key":"10.1016\/j.neuroscience.2025.08.041_b0110","first-page":"S2","article-title":"The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease","volume":"26","author":"Fox","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuroscience.2025.08.041_b0115","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson's disease","volume":"33","author":"Fox","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuroscience.2025.08.041_b0120","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.nbd.2011.01.024","article-title":"Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease","volume":"42","author":"Francardo","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuroscience.2025.08.041_b0125","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00221-018-5390-4","article-title":"Effect of the selective 5-HT(2A) receptor antagonist EMD-281,014 on L-DOPA-induced abnormal involuntary movements in the 6-OHDA-lesioned rat","volume":"237","author":"Frouni","year":"2019","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.neuroscience.2025.08.041_b0130","article-title":"Corticostriatal plastic changes in experimental L-DOPA-induced dyskinesia","volume":"2012","author":"Ghiglieri","year":"2012","journal-title":"Parkinsons Dis"},{"key":"10.1016\/j.neuroscience.2025.08.041_b0135","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S0140-6736(14)60683-8","article-title":"Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial","volume":"384","author":"Group","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.neuroscience.2025.08.041_b0140","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0014-2999(01)00737-3","article-title":"Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys","volume":"412","author":"Hadj Tahar","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuroscience.2025.08.041_b0145","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1111\/ejn.14679","article-title":"The highly selective mGlu(2) receptor positive allosteric modulator LY-487,379 alleviates l-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease","volume":"51","author":"Hamadjida","year":"2020","journal-title":"Eur. J. Neurosci."},{"issue":"194","key":"10.1016\/j.neuroscience.2025.08.041_b0150","first-page":"e195","article-title":"5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA","volume":"33","author":"Huot","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuroscience.2025.08.041_b0155","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/mds.27565","article-title":"Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques","volume":"34","author":"Johnston","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuroscience.2025.08.041_b0160","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1016\/j.euroneuro.2015.09.018","article-title":"The effects of the monoamine stabilizer (-)-OSU6162 on craving in alcohol dependent individuals: a human laboratory study","volume":"25","author":"Khemiri","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuroscience.2025.08.041_b0165","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1017\/neu.2014.16","article-title":"Tolerability and efficacy of the monoaminergic stabilizer (-)-OSU6162 (PNU-96391A) in Huntington's disease: a double-blind cross-over study","volume":"26","author":"Kloberg","year":"2014","journal-title":"Acta Neuropsychiatr"},{"key":"10.1016\/j.neuroscience.2025.08.041_b0170","article-title":"The 5-HT(2A\/2C) inverse agonist nelotanserin alleviates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset","author":"Kwan","year":"2023","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuroscience.2025.08.041_b0175","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1124\/jpet.111.179416","article-title":"Behavioral and cellular modulation of L-DOPA-induced dyskinesia by beta-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat","volume":"337","author":"Lindenbach","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuroscience.2025.08.041_b0180","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/BF00231786","article-title":"Haloperidol-increased muscle tone in rats as a model of parkinsonian rigidity","volume":"109","author":"Lorenc-Koci","year":"1996","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.neuroscience.2025.08.041_b0185","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","article-title":"Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease","volume":"15","author":"Lundblad","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuroscience.2025.08.041_b0190","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.expneurol.2009.05.033","article-title":"Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model","volume":"219","author":"Munoz","year":"2009","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuroscience.2025.08.041_b0195","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1124\/jpet.106.102905","volume":"318","author":"Natesan","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"Suppl 3","key":"10.1016\/j.neuroscience.2025.08.041_b0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1468-1331.9.s3.1.x","article-title":"5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy","volume":"9","author":"Nicholson","year":"2002","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.neuroscience.2025.08.041_b0205","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1017\/neu.2017.35","article-title":"A randomised controlled trial of the monoaminergic stabiliser (-)-OSU6162 in treatment of myalgic encephalomyelitis\/chronic fatigue syndrome","volume":"30","author":"Nilsson","year":"2018","journal-title":"Acta Neuropsychiatr"},{"key":"10.1016\/j.neuroscience.2025.08.041_b0210","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1017\/neu.2020.22","article-title":"Effect of the monoaminergic stabiliser (-)-OSU6162 on mental fatigue following stroke or traumatic brain injury","volume":"32","author":"Nilsson","year":"2020","journal-title":"Acta Neuropsychiatr"},{"key":"10.1016\/j.neuroscience.2025.08.041_b0215","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1176\/ajp.152.10.1444","article-title":"D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients","volume":"152","author":"Nordstrom","year":"1995","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuroscience.2025.08.041_b0220","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1523\/JNEUROSCI.15-05-03863.1995","article-title":"Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test","volume":"15","author":"Olsson","year":"1995","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuroscience.2025.08.041_b0225","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1172\/JCI71640","article-title":"Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients","volume":"124","author":"Politis","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neuroscience.2025.08.041_b0230","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ejphar.2012.10.039","article-title":"The dopaminergic stabilizer pridopidine decreases expression of L-DOPA-induced locomotor sensitisation in the rat unilateral 6-OHDA model","volume":"698","author":"Ponten","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuroscience.2025.08.041_b0235","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s00702-008-0038-3","article-title":"Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization","volume":"115","author":"Rung","year":"2008","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.neuroscience.2025.08.041_b0240","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00210-011-0641-y","article-title":"Effects of the dopamine stabilizers (S)-(-)-OSU6162 and ACR16 on prolactin secretion in drug-naive and monoamine-depleted rats","volume":"384","author":"Rung","year":"2011","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.neuroscience.2025.08.041_b0245","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/mp.2012.3","article-title":"The dopamine stabilizers ACR16 and (-)-OSU6162 display nanomolar affinities at the sigma-1 receptor","volume":"18","author":"Sahlholm","year":"2013","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuroscience.2025.08.041_b0250","doi-asserted-by":"crossref","unstructured":"Siskind, D., McCartney, L., Goldschlager, R., Kisely, S., Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br. J. Psychiatry 209, 385\u2013392, doi: 10.1192\/bjp.bp.115.177261.","DOI":"10.1192\/bjp.bp.115.177261"},{"key":"10.1016\/j.neuroscience.2025.08.041_b0255","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1021\/jm00043a013","article-title":"Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships","volume":"37","author":"Sonesson","year":"1994","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuroscience.2025.08.041_b0260","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.neuropharm.2005.12.004","article-title":"Serotonin 2A receptor antagonist treatment reduces dopamine D1 receptor-mediated rotational behavior but not L-DOPA-induced abnormal involuntary movements in the unilateral dopamine-depleted rat","volume":"50","author":"Taylor","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuroscience.2025.08.041_b0265","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/npp.2014.195","article-title":"The dopamine stabilizer (-)-OSU6162 occupies a subpopulation of striatal dopamine D2\/D3 receptors: an [(11)C]raclopride PET study in healthy human subjects","volume":"40","author":"Tolboom","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuroscience.2025.08.041_b0270","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.pbb.2008.04.010","article-title":"A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model","volume":"90","author":"Vanover","year":"2008","journal-title":"Pharmacol. Biochem. Behav"},{"key":"10.1016\/j.neuroscience.2025.08.041_b0275","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1006\/nbdi.2002.0499","article-title":"L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function","volume":"10","author":"Winkler","year":"2002","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuroscience.2025.08.041_b0280","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1124\/dmd.32.4.398","article-title":"Comparison of prediction methods for in vivo clearance of (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride, a dopamine D2 receptor antagonist, in humans","volume":"32","author":"Yamazaki","year":"2004","journal-title":"Drug Metab. Dispos."}],"container-title":["Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452225008899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452225008899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T20:49:55Z","timestamp":1758660595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306452225008899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":56,"alternative-id":["S0306452225008899"],"URL":"https:\/\/doi.org\/10.1016\/j.neuroscience.2025.08.041","relation":{},"ISSN":["0306-4522"],"issn-type":[{"value":"0306-4522","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The dopamine stabilizer (-)-OSU6162 attenuates levodopa-induced dyskinesia in the unilateral 6-hydroxydopamine rat model of Parkinson\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuroscience.2025.08.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of International Brain Research Organization (IBRO).","name":"copyright","label":"Copyright"}]}}